A recent Health Canada inspection of the country's only flu vaccine production plant identified 10 issues that need to be addressed, a report from the regulatory agency reveals.
Botox-maker Allergan says it is cutting about 13 percent of its workforce, or roughly 1,500...
AbbVie has reached a roughly $55 billion deal to combine with British counterpart Shire and...
Humphrey and Yu are part of an industry of investigators who help corporate clients screen potential partners and employees or watch for embezzlement and other employee misconduct.
The generic drug maker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion.
The measure had been in the works for nearly two years, since a nationwide meningitis outbreak linked to the now-closed New England Compounding Center in Framingham. A tainted steroid produced by the company was blamed for 64 deaths and hundreds of illnesses.
Shares of Anacor Pharmaceuticals Inc. climbed after federal regulators approved its first drug, the toenail fungus treatment Kerydin, a few weeks ahead of schedule.
The European Union's antitrust body is imposing a fine of $580 million on France's pharmaceutical company Servier and five producers of generic medicines for distorting competition.
U.S. drugmaker AbbVie is boosting its offer for Shire by 11 percent to about $51.3 billion, hoping it will be enough to pique the interest of its British counterpart.
Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments.
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
The bill stemmed from a nationwide meningitis outbreak that authorities blamed on a tainted steroid produced by the now-closed New England Compounding Center in Framingham. The outbreak resulted in 64 deaths and hundreds of illnesses.
Check out some of this week's top headlines from across Manufacturing.net, from the House planning to sue Obama for failing to carry out the laws passed by Congress to China creating thousands of U.S. jobs.
When it comes to flu vaccines, a federal panel says a squirt in the nose is better than a shot in the arm for young children.
Federal health officials are warning consumers who use popular anti-acne treatments about rare but potentially deadly allergic reactions that can cause swelling of the face and difficulty breathing.
Porcine epidemic diarrhea has killed millions of baby pigs since it showed up in the United States last year, and pork prices have been rising for months. For consumers, the worst may be yet to come because the most deaths happened last winter.
GSK received a letter of warning from the FDA about conditions at its manufacturing facility at Ste-Foy, Que., where the company makes flu vaccine for the Canadian and U.S. markets.
Novartis Pharma K.K. violated Japan's personal information protection law and ethical guidelines in a clinical study, led by the University of Tokyo, of a leukemia drug, the university's investigation panel said Tuesday.
Dublin-based drugmaker Shire said it has rejected an unsolicited $46.2 billion offer from AbbVie Inc., arguing that it fundamentally undervalues the company and its prospects.
Biotech drugmaker Endocyte said Tuesday it has regained rights to an experimental cancer drug from Merck & Co., after the treatment failed in a key study last month.
Valeant, which is based in Canada, has teamed up with Bill Ackman's Pershing Square Capital Management to try to purchase Allergan. The two companies went public with their takeover attempt in April and have increased their offer several times.
Under pressure from Congress, celebrity Dr. Mehmet Oz is offering to help "drain the swamp" of unscrupulous marketers using his name to peddle so-called miracle pills to millions of Americans desperate to lose weight.
A pharmaceutical company is locating its headquarters in Charleston, a move expected to create about 40 new jobs over the next five years.
In a medical version of speed dating, doctors will sort through multiple experimental drugs and match patients to the one most likely to succeed based on each person's unique tumor gene profile.
Valeant Pharmaceuticals aims to take its bid for Allergan to the Botox maker's shareholders after Allegan's board unanimously rejected its latest offer of about $53 billion.
Different parts of the federal government describe the problem — and potential solutions — of abuse with Vicodin, OxyContin and other opioid drugs in different terms.
Allergan's board is unanimously rejecting the latest takeover bid from Valeant Pharmaceuticals, and the Botox maker says the offer isn't even worth talking about.
- Page 1